Publication:
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists

Simple item page
dc.contributor.authorFusco, Nicola
dc.contributor.authorRagazzi, Moira
dc.contributor.authorSajjadi, Elham
dc.contributor.authorVenetis, Konstantinos
dc.contributor.authorPiciotti, Roberto
dc.contributor.authorMorganti, Stefania
dc.contributor.authorSantandrea, Giacomo
dc.contributor.authorFanelli, Giuseppe Nicolò
dc.contributor.authorDespini, Luca
dc.contributor.authorInvernizzi, Marco
dc.contributor.authorCerbelli, Bruna
dc.contributor.authorScatena, Cristian
dc.contributor.authorCriscitiello, Carmen
dc.date.accessioned2023-02-02T09:39:39Z
dc.date.available2023-02-02T09:39:39Z
dc.date.issued2021
dc.description.abstractEstrogen receptor (ER) status assessment by immunohistochemistry (IHC) is the gold standard test for the identification of patients with breast cancer who may benefit from endocrine therapy (ET). Whilst most ER+ breast cancers have a high IHC score, about 3% of cases display a low positivity, with 1% to 10% of cells being weakly stained. These tumors are generally classified within the luminal-like category; however, their risk profile seems to be more similar to that of ERnegative breast cancers. The decision on ET for patients with a diagnosis of ER-low breast cancer should be carefully considered in light of the risks and possible benefits of the treatment. Potential pitfalls hinder pathologists and oncologists from establishing an appropriate threshold for "low positivity". Furthermore, several pre-analytical and analytical variables might trouble the pathological identification of these clinically challenging cases. In this review, we sought to discuss the adversities that can be accounted for the pathological identification of ER-low breast cancers in real-world clinical practice, and to provide practical suggestions for the perfect ER testing in light of the most updated recommendations and guidelines.es
dc.formatapplication/pdfes
dc.format.extent11es
dc.identifier.citationHistology and Histopathology Vol. 36, nÂş12 (2021)
dc.identifier.doihttps://doi.org/10.14670/HH-18-376
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/128084
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiaciĂłn externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBreast canceres
dc.subjectBiomarkerses
dc.subjectER-lowes
dc.subjectEstrogen receptores
dc.subjectLow positivees
dc.subjectImmunohistochemistryes
dc.subjectQuality controles
dc.subjectEndocrine therapyes
dc.subjectTherapy resistancees
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - PatologĂ­a. Medicina clĂ­nica. OncologĂ­aes
dc.titleAssessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologistses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Fusco-36-1235-1245-2021.pdf
Size:
7.4 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.36,nÂş12 (2021)